Sage Therapeutics
Sage Therapeutics to halve its total workforce in radical cost-cutting move
April 8, 2020Research and Development, Sales and Marketing Sage Therapeutics, pharma, staff cuts
Sage Therapeutics has revealed a radical restructuring effort to cut costs and “enable the company to advance its corporate strategy …
Sage Therapeutics’ depression drug falls short at Phase 3
December 6, 2019Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure
Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …
FDA approves first-ever postpartum depression therapy: Sage Therapeutics’ Zulresso
March 20, 2019Research and Development, Sales and Marketing FDA, Sage Therapeutics, depression, pharma, postpartum depression
The FDA has announced its decision to approve Sage Therapeutics’ intraveneous injection Zulresso (brexanolone), marking the first authorisation of a …
Sage Therapeutics stock pops on depression P2 results
December 8, 2017Medical Communications, Research and Development Sage Therapeutics, biotech, drugs, pharma, pharmaceutical
Sage Therapeutics’ stock rocketed after it announced that Phase 2 results for its treatment for major depressive disorder (MDD) were …
Sage scores good but not great P3 postpartum depression drug results
November 10, 2017Medical Communications, Research and Development Sage Therapeutics, biotech, drugs, pharma, pharmaceutical
Sage Therapeutics share price soared 50% on the release that its two Phase 3 trials of brexanolone showed statistically significant …
Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…
July 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics
Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …
